Skip to contents

Ivan O. Rosas, MD
Associate Physician, Brigham and Women's Hospital
Associate Professor of Medicine, Harvard Medical School

Brigham and Women's Hospital
Department of Medicine
Pulmonary
75 Francis Street
Boston, MA 02115


Edit Profile


Research Narrative:

 

The long-term goal of our pulmonary research program is to better understand the role of disease mechanisms that contribute to development and progression of parenchymal lung disease thereby enabling us to develop novel diagnostic and therapeutic strategies.

Robust homeostatic mechanisms preserve human lung health from early age through adult years, however maturity can be associated with the development of parenchymal lung diseases. Our research studies focus on Idiopathic Pulmonary Fibrosis (IPF) and Chronic Obstructive Pulmonary Disease (COPD), disorders commonly observed in aging males with a prior history of tobacco exposure. Our laboratory employs cutting edge genomic technologies and animal models to determine how select molecular derangements contribute to development and progression of parenchymal lung disease associated with established risk factors including smoking, aging, gender and the metabolic syndrome (Morse D, Rosas IO. Tobacco smoke-induced lung fibrosis and emphysema. Annu Rev Physiol. 2014; 76:493-513).

Our clinical research studies have shown that subclinical pulmonary fibrosis can be detected in at-risk populations including families affected with pulmonary fibrosis, smokers and patients affected with rheumatoid arthritis (Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med. 2012 Jun 1; 185(11):1147-53). These studies are transformative as they provide critical evidence that prevention is feasible in common parenchymal lung diseases associated with high morbidity and mortality (Rosas IO, Dellaripa PF, Lederer DJ et al. Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014 Apr; 11 Suppl 3:S169-77).


Education:
Universidad Nacional de Colombia, 1991, MD

Publications (Pulled from Harvard Catalyst Profiles):

1. Hobbs BD, Putman RK, Araki T, Nishino M, Gudmundsson G, Gudnason V, Eiriksdottir G, Zilhao Nogueira NR, Dupuis J, Xu H, O'Connor GT, Manichaikul A, Nguyen J, Podolanczuk AJ, Madahar P, Rotter JI, Lederer DJ, Barr RG, Rich SS, Ampleford EJ, Ortega VE, Peters SP, O'Neal WK, Newell JD, Bleecker ER, Meyers DA, Allen RJ, Oldham JM, Ma SF, Noth I, Jenkins RG, Maher TM, Hubbard RB, Wain LV, Fingerlin TE, Schwartz DA, Washko GR, Rosas IO, Silverman EK, Hatabu H, Cho MH, Hunninghake GM. Overlap of Genetic Risk Between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 Jul 24.

2. Putman RK, Gudmundsson G, Axelsson GT, Hida T, Honda O, Araki T, Yanagawa M, Nishino M, Miller ER, Eiriksdottir G, Gudmundsson EF, Tomiyama N, Honda H, Rosas IO, Washko GR, Cho MH, Schwartz DA, Gudnason V, Hatabu H, Hunninghake GM. Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality. Am J Respir Crit Care Med. 2019 Jul 15; 200(2):175-183.

3. Tang Y, El-Chemaly S, Taveira-Dasilva A, Goldberg HJ, Bagwe S, Rosas IO, Moss J, Priolo C, Henske EP. Metabolic Changes in Patients With Lymphangioleiomyomatosis Treated With Sirolimus and Hydroxychloroquine. Chest. 2019 Jul 09.

4. Harmouche R, Ash SY, Putman RK, Hunninghake GM, San Jose Estepar R, Martinez FJ, Choi AM, Lynch DA, Hatabu H, Han MK, Bowler RP, Kalhan R, Rosas IO, Washko GR, San Jose Estepar R. Objectively Measured Chronic Lung Injury on Chest CT. Chest. 2019 Jun 22.

5. Courtwright AM, Lamattina AM, Louis PH, Trindade AJ, Burkett P, Imani J, Shrestha S, Divo M, Keller S, Rosas IO, Goldberg HJ, El-Chemaly S. Hyaluronan and LYVE-1 and allograft function in lung transplantation recipients. Sci Rep. 2019 Jun 21; 9(1):9003.

6. Tsoyi K, Osorio JC, Chu SG, Fernandez IE, De Frias SP, Sholl L, Cui Y, Tellez CS, Siegfried JM, Belinsky SA, Perrella MA, El-Chemaly S, Rosas IO. Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness. Am J Respir Cell Mol Biol. 2019 Jun; 60(6):659-666.

7. Lee CM, He CH, Park JW, Lee JH, Kamle S, Ma B, Akosman B, Cotez R, Chen E, Zhou Y, Herzog EL, Ryu C, Peng X, Rosas IO, Poli S, Bostwick CF, Choi AM, Elias JA, Lee CG. Chitinase 1 regulates pulmonary fibrosis by modulating TGF-ß/SMAD7 pathway via TGFBRAP1 and FOXO3. Life Sci Alliance. 2019 Jun; 2(3).

8. Stump B, Shrestha S, Lamattina AM, Louis PH, Cho W, Perrella MA, Ai X, Rosas IO, Wagner FF, Priolo C, Astin J, El-Chemaly S. Glycogen synthase kinase 3-ß inhibition induces lymphangiogenesis through ß-catenin-dependent and mTOR-independent pathways. PLoS One. 2019; 14(4):e0213831.

9. Sparks JA, He X, Huang J, Fletcher EA, Zaccardelli A, Friedlander HM, Gill RR, Hatabu H, Nishino M, Murphy DJ, Iannaccone CK, Mahmoud TG, Frits ML, Lu B, Rosas IO, Dellaripa PF, Weinblatt ME, Karlson EW, Shadick NA, Doyle TJ. Rheumatoid Arthritis Disease Activity Predicting Incident Clinically Apparent Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Prospective Cohort Study. Arthritis Rheumatol. 2019 Apr 05.

10. Miller ER, Putman RK, Diaz AA, Xu H, San José Estépar R, Araki T, Nishino M, Poli de Frías S, Hida T, Ross J, Coxson H, Dupuis J, O'Connor GT, Silverman EK, Rosas IO, Hatabu H, Washko G, Hunninghake GM. Increased Airway Wall Thickness in Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2019 Apr; 16(4):447-454.